Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue

• US 6,982,248 B2
• Filed: 05/09/2001
• Issued: 01/03/2006
• Est. Priority Date: 10/08/1998
• Status: Expired due to Fees

• Current Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Coolidge, Thomas R., Ehlers, Mario R. W.
• Primary Examiner(s): Carlson, Karen Cochrane
• Assistant Examiner(s): Liu, Samuel W.
• Application Number:
  US09/851,738
• Publication Number:
  US 20020055460A1
• Time in Patent Office: 1,700 Days
• Field of Search: 514/2, 514/3, 514/21, 530/308, 530/324, 530/350, 424/198.1, 424/278.1
• US Class Current: 514/11.7
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 39/06 Free radical scavengers or antioxidants
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Individuals in need of treatment of ischemia-related reperfusion are treated, preferably intravenously, with a composition which includes a compound which binds to a receptor for the glucagon-like peptide-1. The invention relates to both the method and compositions for such treatment.

Claims

1. A method for preventing or ameliorating a decrease in a function of a tissue, wherein the tissue has undergone an ischemia-reperfusion event sufficient to cause cell death, or reversible or irreversible cell damage in said tissue, comprising administering to an individual an effective amount of a composition comprising a compound that activates a receptor for glucagon-like peptide-1 (GLP-1) in a pharmaceutical carrier.

2. The method of claim 1 wherein the compound is a GLP-1 (7-36) amide or a biologically active analog thereof.

3. The method of claim 1 wherein the pharmaceutical carrier is selected from the group consisting of saline, buffered saline, dextrose, water, glycerol, ethanol, lactose, phosphate, mannitol, arginine, treholose, and combinations thereof.

4. The method of claim 1 wherein administering to the individual-is at a dose level of 0.1 pmol/kg/min to 10 pmol/kg/min.

5. The method of claim 1 wherein there is concurrent administration of glucose.

6. The method of claim 1 wherein administration commences within 4 hours of an ischemic event.

7. The method of claim 6 wherein administration occurs within 4 hours and is a continuous infusion of the composition.

8. The method of claim 1 wherein the isehemic-reperfusion event arises from a medical procedure that is a surgical event selected from the group consisting of cardiac surgical procedures, organ transplants, traumatic limb amputation and reattachment.

9. The method of claim 1 wherein the ischemic-reperfusion event is concurrent with a gut infarct or a myocardial infarct.

10. The method of claim 1 comprising reperfusion therapy.

20. The method of claim 1, further comprising administering an anti-inflammatory agent.

11. A method for preventing or ameliorating a decrease in a function of a tissue, wherein the tissue has undergone an ischemia-reperfusion event sufficient to cause cell death, or reversible or irreversible cell damage in said tissue, comprising administering to an individual an effective amount of an exendin.

12. The method of claim 11, wherein the exendin is administered at a dose of 0.005 nmol/kg to 20 nmol/kg.

13. The method of claim 11 wherein the pharmaceutical carrier is selected from the group consisting of saline, buffered saline, dextrose, water, glycerol, ethanol, lactose, phosphate, mannitol, arginine, treholose, and combinations thereof.

14. The method of claim 11 wherein there is concurrent administration of glucose.

15. The method of claim 11 wherein administration commences within 4 hours of an ischemic event.

16. The method of claim 11 wherein administration occurs within 4 hours of an ischemic event and is a continuous infusion.

17. The method of claim 11 wherein the ischemic-reperfusion event arises from a medical procedure that is a surgical event selected from the group consisting of cardiac surgical procedures, organ transplants and traumatic limb amputation and reattachment.

18. The method of claim 11 wherein the ischemia-reperfusion event is concurrent with a gut infarct or a myocardial infarct.

19. The method of claim 11, further comprising administering an anti-inflammatory agent.

21. The method of claim 11, wherein the exendin is exendin 3 or exendin 4.

22. The method of claim 11 comprising reperfusion therapy.

23. A method for preventing or ameliorating tissue injury caused by reperfusion of blood flow following a period of ischemia, comprising administering to an individual an effective amount of a compound that activates a receptor for glucagon-like peptide-1.

24. The method of claim 23 wherein the period of ischemia is caused by an event selected from the group consisting of cardiac surgical procedures, organ transplants, and traumatic limb amputation and reattachment.

25. The method of claim 23 further comprising administering an anti-inflammatory agent.

26. The method of claim 23 wherein there is concurrent administration of any one of glucose, potassium or free radical scavenger.

27. The method of claim 23 wherein administration is by subcutaneous or micropressure injection, deep lung insufflation, external or implant pump, depot injection, and other sustained release mechanisms, oral deliver and patch, buccal and other cross skin and membrane mechanism.

28. The method of claim 23 comprising reperfusion therapy.